Hypertension Journal

Register      Login

VOLUME 2 , ISSUE 3 ( July-September, 2016 ) > List of Articles


Clinical Perspective

David A Calhoun

Citation Information : Calhoun DA. Clinical Perspective. Hypertens J 2016; 2 (3):153-159.

DOI: 10.5005/jp-journals-10043-0048

Published Online: 01-03-2016

Copyright Statement:  Copyright © 2016; The Author(s).


How to cite this article

Calhoun DA. Clinical Perspective. Hypertens J 2016;2(3):153-159.

PDF Share
  1. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51:1403-1419.
  2. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011 May;57(5):898-902.
  3. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension 2011 Jun;57(6):1076-1080.
  4. What is the prevalence of resistant hypertension in the United States? Curr Opin Cardiol 2012 Jul;27(4):386-391.
  5. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc 2013 Oct;88(10):1099-1107.
  6. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014 Nov;64(5):1012-1021.
  7. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002 Nov-Dec;4(6):393-404.
  8. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement. J Am Soc Hypertens 2016 Jun;10(6):493-499.
  9. Epidemiological perspective of body position and arm level in blood pressure measurement. Blood Press 1994 May;3(3):156-163.
  10. Terminal digit preference and single-number preference in the Syst-Eur trial: influence of quality control. Blood Press Monit 2002 Jun;7(3):169-177.
  11. General Practice Hypertension Study G. Selective recording in blood pressure readings may increase subsequent mortality. QJM 2002 Sep;95(9):571-577.
  12. Characteristics, drug combinations and dosages of primary care patients with uncontrolled ambulatory blood pressure and high medication adherence. J Am Soc Hypertens 2013 Nov-Dec;7(6):471-476.
  13. Appropriate time interval to repeat ambulatory blood pressure monitoring in patients with white-coat resistant hypertension. Hypertension 2012 Feb;59(2):384-389.
  14. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 2013 Apr;31(4):766-774.
  15. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens 2013 Dec;31(12):2455-2461.
  16. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013 Oct;62(4):691-697.
  17. Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension 2002 May;39(5):982-988.
  18. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008 Jun;168(11):1159-1164.
  19. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyper-aldosteronism: a prospective clinical study. Hypertension 2010 May;55(5):1137-1142.
  20. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension 2006 Mar;47(3):352-358.
  21. Are chlorthali-done and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens 2005 Jun;7(6):354-356.
  22. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002 Dec;40(6):892-896.
  23. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004 Nov;22(11):2217-2226.
  24. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001 Apr;37(4):699-705.
  25. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens 2003 May;17(5):349-352.
  26. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003 Nov;16(11 Pt 1):925-930.
  27. Management of resistant arterial hypertension: role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010 Nov;28(11):2329-2335.
  28. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007 Apr;49(4):839-845.
  29. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension 2010 Jan;55(1):147-152.
  30. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): A randomised, double-blind, crossover trial. Lancet 2015 Nov;386(10008):2059-2068.
  31. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009 Apr;373(9671):1275-1281.
  32. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010 Dec;376(9756):1903-1909.
  33. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014 Apr;370(15):1393-1401.
  34. Randomized sham-controlled trial of renal sympathetic denervation in mild resistant hypertension. Hypertension 2015 Mar;65(4):1202-1208.
  35. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 2015 May;385(9981):1957-1965.
  36. J Hypertens 2016 Sep;34(9):1863-1871.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.